Expert Interview
Discussing the Adagrasib/Cetuximab Combination Therapy in KRAS G12C–Mutant Colorectal Cancer ahead of the PDUFA
Ticker(s): BMYInstitution: Roswell Park Comprehensive Cancer Center
- Associate Professor Division of GI Oncology, Associate Director Early Phase Clinical Trial, and Associate Director for Solid Tumor at Roswell Park.
- Previously while at Merck led several global Phase I-III immuno-oncology trials, including Keynote 177 and 164 in MSI-H colorectal cancer, and Keynote 651 in non-MSI-H CRC
- Current focus on early stage trials in head and neck cancer, patient care and clinical/translational research.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
